Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C

HMG CoA reductase inhibition suppresses in vitro HCV replication through depletion of cellular sterol proteins such as geranylgeraniol. Our aims were to prospectively evaluate the changes in serum and lipid fraction HCV RNA with Rosuvastatin in non-responder (NR) patients with CHC. A total of 11 pat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Patel, K., Jhaveri, R., George, J., Qiang, G., Kenedi, C., Brown, K., Cates, C., Zekry, A., Tillmann, H. L., Elliott, L., Kilaru, R., Albrecht, J., Conrad, A., McHutchison, J. G
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3826439/
https://ncbi.nlm.nih.gov/pubmed/20367801
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2893.2010.01310.x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi